Stevens Capital Management’s Moderna MRNA Stock Holding History

Stevens Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$278K	Buy	+3,970	New	+$205K	0.07%	190
2024 Q1	–	Sell	-7,426	Closed	-$739K	–	325
2023 Q4	$739K	Sell	7,426 -28,660	-79%	-$2.41M	0.18%	117
2023 Q3	$3.73M	Buy	36,086 +23,583	+189%	+$2.63M	1.08%	16
2023 Q2	$1.52M	Sell	12,503 -27,374	-69%	-$3.65M	0.31%	70
2023 Q1	$6.12M	Buy	39,877 +29,724	+293%	+$4.9M	1.52%	15
2022 Q4	$1.82M	Buy	+10,153	New	+$1.66M	1.15%	22
2022 Q3	–	Sell	-54,154	Closed	-$7.74M	–	165
2022 Q2	$7.74M	Buy	54,154 +31,427	+138%	+$4.49M	5.38%	5
2022 Q1	$3.92M	Buy	22,727 +164	+0.7%	+$27.6K	0.85%	28
2021 Q4	$5.73M	Buy	+22,563	New	+$6.6M	1.32%	19
2019 Q3	–	Sell	-75,249	Closed	-$1.1M	–	687
2019 Q2	$1.1M	Buy	+75,249	New	+$1.62M	0.05%	351

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Stevens Capital Management's MRNA Position: Q2 2026 in Review

Stevens Capital Management opened a new position in Moderna (MRNA) in Q2 2026: 3,970 shares worth $278K. The stake represents 0.07% of the portfolio and ranks #190 among its holdings. This is a return to the name: Stevens Capital Management previously reported a position in MRNA as recently as Q4 2023.

Stevens Capital Management first reported a position in MRNA in Q2 2019 and has held it in 10 quarters since. The position peaked at $7.74M in Q2 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Stevens Capital Management held 3,970 shares of Moderna worth $278K as of Q2 2026.
Moderna was a new Stevens Capital Management position in Q2 2026.
Moderna made up 0.07% of Stevens Capital Management's portfolio in Q2 2026, its #190 holding.
Stevens Capital Management first reported a position in Moderna in Q2 2019 and has held it in 10 quarters since.
Stevens Capital Management's Moderna position peaked at $7.74M in Q2 2022.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Stevens Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.